BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kawagishi N, Suda G, Kimura M, Maehara O, Shimazaki T, Yamada R, Kitagataya T, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Kudo Y, Nishida M, Sakamoto N. High serum angiopoietin‐2 level predicts non‐regression of liver stiffness measurement‐based liver fibrosis stage after direct‐acting antiviral therapy for hepatitis C. Hepatol Res 2020;50:671-81. [DOI: 10.1111/hepr.13490] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Sadeghi A, Amiri R, Akbarpour E, Mirminachi B, Sharifi AH, Merat S. Changes in liver fibrosis in patients with chronic hepatitis C after successful direct-acting antiviral therapy. Int J Clin Pract 2021;75:e14145. [PMID: 33709413 DOI: 10.1111/ijcp.14145] [Reference Citation Analysis]
2 Tokuchi Y, Suda G, Kimura M, Maehara O, Kitagataya T, Kubo A, Yoshida S, Fu Q, Yang Z, Hosoda S, Ohara M, Yamada R, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N. Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals. Sci Rep 2021;11:16616. [PMID: 34400736 DOI: 10.1038/s41598-021-96203-z] [Reference Citation Analysis]
3 Suda G, Sakamoto N. Recent advances in the treatment of hepatitis C virus infection for special populations and remaining problems. J Gastroenterol Hepatol 2021;36:1152-8. [PMID: 32667068 DOI: 10.1111/jgh.15189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Rockey DC, Friedman SL. Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside. Gastroenterology 2021;160:1502-1520.e1. [PMID: 33529675 DOI: 10.1053/j.gastro.2020.09.065] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
5 Shigesawa T, Suda G, Kimura M, Maehara O, Tokuchi Y, Kubo A, Yamada R, Furuya K, Baba M, Kitagataya T, Suzuki K, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma. PLoS One 2021;16:e0247728. [PMID: 33647018 DOI: 10.1371/journal.pone.0247728] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Higuchi M, Tamaki N, Kurosaki M, Inada K, Kirino S, Yamashita K, Hayakawa Y, Sekiguchi S, Osawa L, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Enomoto N, Izumi N. Changes of liver stiffness measured by magnetic resonance elastography during direct-acting antivirals treatment in patients with chronic hepatitis C. J Med Virol 2021;93:3744-51. [PMID: 32890408 DOI: 10.1002/jmv.26490] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Shigesawa T, Suda G, Kimura M, Shimazaki T, Maehara O, Yamada R, Kitagataya T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma. JGH Open 2020;4:880-8. [PMID: 33102759 DOI: 10.1002/jgh3.12339] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
8 Shimada S, Kamiyama T, Kakisaka T, Orimo T, Nagatsu A, Asahi Y, Sakamoto Y, Kamachi H, Kudo Y, Nishida M, Taketomi A. The impact of elastography with virtual touch quantification of future remnant liver before major hepatectomy. Quant Imaging Med Surg 2021;11:2572-85. [PMID: 34079724 DOI: 10.21037/qims-20-1073] [Reference Citation Analysis]
9 Osawa Y, Yoshio S, Aoki Y, Korenaga M, Imamura M, Oide T, Okawara M, Kawai H, Tsutsui Y, Yoshida Y, Yoshikawa S, Mori T, Yamazoe T, Kanto T. Blood angiopoietin-2 predicts liver angiogenesis and fibrosis in hepatitis C patients. BMC Gastroenterol 2021;21:55. [PMID: 33557759 DOI: 10.1186/s12876-021-01633-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Isaac A, El Sakaty TM, Hussein SH, Rasmy HS. Angiopoietin-2 as a predictor of fibrosis regression in chronic hepatitis C virus patients after direct-acting antiviral drugs. Egypt J Intern Med 2021;33. [DOI: 10.1186/s43162-021-00086-5] [Reference Citation Analysis]
11 Kawagishi N, Suda G, Kimura M, Maehara O, Yamada R, Tokuchi Y, Kubo A, Kitagataya T, Shigesawa T, Suzuki K, Ohara M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Kudo Y, Nishida M, Sakamoto N. Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C. Sci Rep 2021;11:9207. [PMID: 33911145 DOI: 10.1038/s41598-021-88632-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]